RTN4: Reticulon-4
Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on RTN4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Atinumab | Phase 2 | Novartis Pharmaceuticals | Antibody | InhibitorReticulon-4 inhibitor | 0 |
| Ozanezumab | Phase 2 | GSK | Antibody | InhibitorReticulon-4 inhibitor | 0 |
- Obesity disorder0.38
- Neurodegenerative disease0.26
- Skin cancer0.23
- Sensorineural hearing loss disorder0.21
- Hearing loss disorder0.21
- Alcohol drinking0.18
- Type 2 diabetes mellitus0.14
- Cervical carcinoma0.14
- Endocarditis0.12
- Hepatocellular carcinoma0.10
- Neoplasm0.10
- Amyotrophic lateral sclerosis0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712895, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9NQC3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets